Lars Abrahmsen Net Worth

The estimated Net Worth of Lars B. Abrahmsen is at least $222 Thousand dollars as of 1 October 2021. Lars Abrahmsen owns over 50,000 units of Aprea Therapeutics stock worth over $222,180 and over the last 5 years he sold APRE stock worth over $0. In addition, he makes $0 as Senior Vice President and Chief Scientific Officer at Aprea Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lars Abrahmsen APRE stock SEC Form 4 insiders trading

Lars has made over 2 trades of the Aprea Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of APRE stock worth $46,000 on 1 October 2021.

The largest trade he's ever made was exercising 50,000 units of Aprea Therapeutics stock on 1 October 2021 worth over $46,000. On average, Lars trades about 12,500 units every 2 days since 2019. As of 1 October 2021 he still owns at least 69,000 units of Aprea Therapeutics stock.

You can see the complete history of Lars Abrahmsen stock trades at the bottom of the page.

Lars Abrahmsen biography

Dr. Lars B. Abrahmsen Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. Dr. Abrahmsen has more than 30 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, Inc., he has also worked at Swedish Orphan Biovitrum AB, Pharmacia & Upjohn, Inc., Pharmacia Corporation and KabiGen AB. More recently he served as Chief Scientific Officer at Affibody AB from 2004-2010 and as SVP of Protein Therapeutics at Algeta ASA from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.

How old is Lars Abrahmsen?

Lars Abrahmsen is 63, he's been the Senior Vice President and Chief Scientific Officer of Aprea Therapeutics since 2014. There are 3 older and 12 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.

Insiders trading at Aprea Therapeutics

Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant..., and John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.

What does Aprea Therapeutics do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Complete history of Lars Abrahmsen stock trades at Aprea Therapeutics

Aprea Therapeutics executives and stock owners

Aprea Therapeutics executives and other stock owners filed with the SEC include:

• Christian Schade,
  Chairman of the Board, President, Chief Executive Officer
• Scott Coiante,
  Chief Financial Officer, Senior Vice President, Secretary
• Eyal Attar,
  Senior Vice President, Chief Medical Officer
• Christian S. Schade,
  Pres, CEO & Chairman
• Dr. Eyal C. Attar M.D.,
  Sr. VP & Chief Medical Officer
• Scott M. Coiante,
  Sr. VP, Company Sec. & CFO
• John Henneman,
  Lead Independent Director
• Bernd Seizinger,
  Independent Director
• Guido Magni,
  Independent Director
• Johan Christenson,
  Independent Director
• Dr. Oren Gilad Ph.D.,
  Co-Founder, Pres & Director
• Richard Peters,
  Director
• Fouad Namouni,
  Director
• Michael Kelly,
  Director
• Gregory Wessels,
  Chief Commercial Officer
• Gregory Korbel,
  Vice President - Business Development
• Lars Abrahmsen,
  Senior Vice President, Chief Scientific Officer
• Andrea Epstein,
  Controller
• Dr. Michel Afargan Ph.D.,
  Head of Pharmacology Devel.
• Hank Breslin,
  Head of Medicinal Chemistry
• Dr. Rifat Pamukcu M.D.,
  Chief Medical Advisor & Director
• Dr. Dansu Li Ph.D.,
  Head of Technology
• Dr. Lars B. Abrahmsen,
  Sr. VP & Chief Scientific Officer
• Dr. Gregory A. Korbel Ph.D.,
  Sr. VP & Chief Bus. Officer
• Ventures Iv, L.P.5 Am Co In...,
  
• Marc Duey,
  Director
• Michael Grissinger,
  Director
• Rifat Pamukcu,
  Director
• Ventures Iv, L.P.5 Am Co In...,
  
• V Luxco S.A R.L.Versant Ven...,
  
• Oren Gilad,
  President, CEO
• Investments Ab Karolinska D...,
  
• Scott M Rocklage,
  Director
• V Luxco S.A R.L.Versant Ven...,
  
• Vantage I, L.P.Versant Vant...,
  
• Group, Llc Green Jeremy Red...,
  
• Vii, L.P.Health Cap Vii Gp ...,
  
• Jonathan Hepple,
  
• John P. Hamill,
  SrVP/CFO/Prin Fin & Acct Ofcr
• Gabriela Gruia,
  Director
• Jean Pierre Bizzari,
  Director
• Nadeem Q. Mirza,
  Chief Medical Officer